NCT03626636
A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
A Randomized Controlled, Double-Masked, Crossover Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
Allegro Ophthalmics, LLC·Phase 2·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Dry Age-related Macular Degeneration
- Drug/Device/Intervention
- Risuteganib
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Allegro Ophthalmics, LLC
- Location
- Gilbert,Phoenix,Beverly Hills,Altamonte Springs,Indianapolis,McAllen,San Antonio, United States of America
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Aug 01, 2017
- End date
- Apr 04, 2019
- Enrollment
- 42 participants
Primary outcome
Change in BCVA
Summary
To evaluate the safety and exploratory efficacy of 1.0mg of Luminate® in patients with
 Intermediate Non-Exudative Macular Degeneration
ICD-10 classifications
Peripheral retinal degenerationCorneal degenerationHereditary retinal dystrophyOptic atrophy in diseases classified elsewhereDisorders of choroid and retina
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT03626636
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT03626636 through Pure Global AI's free database. This Phase 2 trial is sponsored by Allegro Ophthalmics, LLC and is currently Completed. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 42 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.